09/17/2018 | Press release | Distributed by Public on 09/17/2018 09:43
Leuven, Belgium, 17 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that it will give two presentations at the Euretina International Congress, which is being held in Vienna, Austria, from 20 to 23 September 2018.
The presentation 'Anti-inflammatory effects of the PlGF neutralizing antibody THR-317 in patients with diabetic macular edema' will be given by Oxurion senior scientist Dr. Michaël Porcu. The presentation will take place at 6pm CET, Friday 21 September at the Free Paper Session 11 on New Drug Treatment & Technology I (Room C1).
THR-317 is a PIGF neutralizing monoclonal antibody being developed for the treatment of Diabetic Macular Edema (DME). THR-317 is in a Phase 2 study evaluating the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab (Lucentis®).
The presentation 'Therapeutic effect of the potent integrin antagonist THR-687 in the cynomolgus laser-induced choroidal neovascularization model confirms its potential as novel treatment for sight-threatening retinal pathologies' will be given by Oxurion scientist Dr. Tjing-Tjing Hu. The presentation will take place on Saturday 22 September at 3.06pm CET at the Free Paper Session 18 on New Drug Treatment & Technology II (Room C4).
THR-687 is a small molecule pan-RGD integrin antagonist being developed to treat a broad range of patients with diabetic eye disease. THR-687 is expected to enter the clinic shortly.
'We are pleased to have the opportunity to present our cutting-edge research in the field of diabetic eye disease at Euretina', said Dr. Patrik De Haes, CEO of Oxurion nv. 'There is a clear unmet medical need for improved treatment options for diabetic eye disease. Oxurion is focused on addressing this need and is developing multiple new therapies, including THR-317 and THR-687, each with the potential to improve on the current standard of care for a number of diabetic eye disease indications.'
Visit Oxurion booth #C228 for meeting up with the Oxurion team.